REVLODEX Trademark

Trademark Overview

On Wednesday, March 4, 2020, a trademark application was filed for REVLODEX with the United States Patent and Trademark Office. The USPTO has given the REVLODEX trademark a serial number of 88820961. The federal status of this trademark filing is REGISTERED as of Tuesday, September 1, 2020. This trademark is owned by Celgene Corporation. The REVLODEX trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations used to treat cancers and immune related diseases
revlodex

General Information

Serial Number88820961
Word MarkREVLODEX
Filing DateWednesday, March 4, 2020
Status700 - REGISTERED
Status DateTuesday, September 1, 2020
Registration Number6141932
Registration DateTuesday, September 1, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 16, 2020

Trademark Statements

Goods and Servicespharmaceutical preparations used to treat cancers and immune related diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 11, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Wednesday, March 18, 2020ASSIGNED TO LIE
Saturday, March 7, 2020NEW APPLICATION ENTERED
Wednesday, March 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 11, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, March 19, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 19, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 8, 2020ASSIGNED TO EXAMINER
Friday, May 8, 2020NON-FINAL ACTION WRITTEN
Friday, May 8, 2020NON-FINAL ACTION E-MAILED
Friday, May 8, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 12, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 13, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 13, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 14, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 27, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 16, 2020PUBLISHED FOR OPPOSITION
Tuesday, June 16, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 1, 2020REGISTERED-PRINCIPAL REGISTER
Friday, December 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 9, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, December 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, December 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, September 1, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, December 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

Related Keywords

revlodex immune related diseases cancers treat preparations used pharmaceutical